USF3

Across TCGA pan-cancer cohorts, USF3 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated USF3 data layer compared with 18 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher USF3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated USF3 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

LIHC, UCEC, and SCLC are the cancer types where USF3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	II,III,IV	0.113	0.723	<.001	37	view →
UCEC	DFS	Median	All	0.963	0.600	<.001	32	view →
SCLC	OS	Median	II,III,IV	0.110	0.665	<.001	18	view →
HNSC	OS	Median	All	0.454	0.771	.013	7	view →
LUSC	OS	Median	II,III,IV	0.250	0.778	.007	7	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUAD	OS	Median	II,III,IV	0.245	0.749	.019	6	view →
BLCA	OS	Median	III,IV	0.759	0.341	.024	5	view →
SKCM	DFS	Median	IV	0.036	0.433	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

USF3–LIHC (OS)

Open the LIHC breakdown →